As millions turn to GLP-1 medications like Ozempic and Mounjaro to reshape their bodies, science is confronting an unintended consequence: the quiet erosion of muscle alongside fat. A new drug, apitegromab, has shown early promise in preserving lean tissue during weight loss, raising the possibility that the body need not pay so steep a price for transformation. The finding invites a deeper question about what it means to lose weight well — not merely less of oneself, but less of the wrong parts.
G1
· Jun 09, 2026
· health
· 3 min read
Medium
Sourcing: Characterized
Novo medicamento apitegromab pode reverter perda muscular de Ozempic
◉
Health & Medicine
2834 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% match
Berlin admits American Ebola patient as outbreak kills 131 in Congo
Folha de S.Paulo · 90% match
Related Coverage
Folha de S.Paulo · Aug 26
Ônibus escolar cai em ribanceira e deixa duas crianças feridas em SC
Ônibus escolar com dez crianças caiu dez metros em ribanceira em Santa Catarina. Duas crianças ficaram feridas e foram h…
G1 · Aug 26 Incêndio em hospital do Paquistão mata ao menos 15 bebêsPelo menos 15 recém-nascidos morreram em incêndio no hospital PIMS em Islamabad, causado por falha no sistema de ar-cond…
G1 · Aug 26 Zelador agredido com paulada evolui na UTI, mas segue internado no DFZelador agredido há 15 dias por homem em situação de rua apresenta melhora clínica na UTI, respondendo a estímulos e com…
Google News · Aug 26 Diretor do Atlético-MG acusa Kaio Jorge de 'maldade e deslealdade' após lance polêmicoDirigente do Atlético-MG acusa Kaio Jorge de jogada maldosa e desleal que resultou em queda do zagueiro Ruan Tressoldi, …
Bias & Framing
⚖
Article presents promising research on apitegromab for muscle preservation in GLP-1 users with balanced skepticism, though relies heavily on colloquial framing and limited study details.
Bias Direction
center-left
Confidence
MED
Sensationalized colloquial framing ('bumbum de Ozempic') combined with cautious scientific reporting. Uses popular terminology to engage readers while maintaining expert skepticism about efficacy claims.
'bumbum de Ozempic' (repeated 4 times)
'canetas emagrecedoras' (weight-loss pens - diminutive/colloquial)
'bumbum mais achatado ou flácido' (flattened/flaccid buttocks - descriptive language emphasizing aesthetic concern)
'efeito colateral' (side effect - frames as negative)
Voices of actual patients experiencing the phenomenon
Perspective from manufacturers (Novo Nordisk, Eli Lilly) on the issue
Nutritionists' or fitness experts' detailed guidance on prevention
Cost-benefit analysis comparing apitegromab treatment to exercise/nutrition interventions
Long-term safety data or expert commentary on apitegromab beyond 'more studies needed'
Geopolitical Impact
🌎
Medical research on muscle-preserving drug has no geopolitical implications; this is a pharmaceutical/health article with no international relations, conflict, or power dynamics.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Apitegromab shows promise in preserving muscle mass during GLP-1 weight-loss treatment, addressing a significant side effect where up to one-third of weight loss comes from muscle rather than fat.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Cosmetic Surgery
Fitness/Wellness Industry
Obesity Treatment Market
Consumers using GLP-1 drugs (Ozempic, Wegovy, Mounjaro) could benefit from improved outcomes with reduced muscle loss and body composition changes. This addresses aesthetic and health concerns, potentially increasing treatment adherence and satisfaction. May reduce demand for cosmetic procedures to address 'Ozempic butt' side effects.
Regulatory agencies (FDA, ANVISA) will need to evaluate apitegromab's efficacy and safety through additional clinical trials before approval. Healthcare systems may need to update obesity treatment guidelines to include combination therapies. Insurance coverage decisions will impact accessibility and market adoption of combination treatments.